Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Long-term effects of early Parkinson's treatments similar

A study published online today in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

"Clinicians and patients often struggle with what is the right initial approach to treating Parkinson's disease," said University of Rochester Medical Center neurologist Kevin Biglan, M.D., M.P.H., the lead author of the paper and a member of the Parkinson's Study Group, an international network of researchers that oversaw the clinical trial.

"This study tells us that, over the long haul, patients on the different drugs end up at roughly the same place in terms of their level of disability and quality of life."

Parkinson's disease is a progressive neurological disorder that erodes a person's control over their movements and speech. Over time, Parkinson's patients may experience stiffness or rigidity of the arms and legs, slowness or lack of movement, and walking difficulties, in addition to tremors in their hands, arms, legs, jaw or face.

The study compared two drugs – levodopa and pramipexole – that are generally employed as the first line of treatment for Parkinson's disease. The two drugs use different mechanisms to counteract the decline in the production of dopamine in the brain that is a result of a progressive loss of cells that secrete the neurochemical. Levodopa is an amino acid that the body metabolizes into dopamine. Pramipexole is a dopamine agonist that binds with dopamine receptors on cells in the brain and mimics the chemical's molecular function.

While levodopa is considered to be better at addressing the motor control symptoms of the disease such as mobility issues and tremors, it is also associated with side effects such as dyskinesia (involuntary movements) and the effectiveness of the drug can diminish, or wear off, over time. Pramipexole is less effective with respect to motor control symptoms and more often causes sleepiness, but is less commonly associated with dyskinesias and wearing off. Pramipexole is often prescribed because clinicians believe it essentially extends the window in which the patient can benefit from levodopa by delaying the initial use of the drug – and its eventually wearing off. Most Parkinson's patients end up taking levodopa at some point regardless of their initial treatment because it is more effective at improving the symptoms of the disease.

The initial study followed 301 Parkinson's patients in 22 sites in the U.S. and Canada over a 2 year period. A sub-set (222) of the group was followed for an additional 4 years. Half the patients were randomly assigned to be initially treated with levodopa and the other half with pramipexole. After 6 years of follow-up, essentially all of the participants (90%) were taking levodopa. The researchers evaluated study participants using tools that measure disability (ability to perform daily activities), side effects, disease severity, and the patient's sleepiness.

The study confirmed that patients who are initially treated with levodopa are more likely to develop motor complications such as dyskinesias and wearing off even 6 years after treatment. However, it also shows that these complications did not have a significant impact on the quality of life or disability of the patients.

"Clinicians and patients still need to establish their treatment priorities to understand unique circumstances that argue in favor of one drug vs. the other," said Biglan. "However, this study should assuage any concerns that the treatment decisions that are made early in the disease will have long-term implications, which does not appear to be the case."

Mark Michaud | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>